Computer-aided quantitative bone scan assessment of prostate cancer treatment response
Computer-aided quantitative bone scan assessment of prostate cancer treatment response
复制标题
DOI：
10.1097/mnm.0b013e3283503ebf
复制
发表时间：
2012-04-01
影响因子：
1.5
通讯作者：
Goldin, Jonathan G.
中科院分区：
文献类型：
--
作者：
Brown, Matthew S.;Chu, Gregory H.;Goldin, Jonathan G.
目的开发和评价一种计算机辅助骨扫描分析技术，以量化肿瘤负荷的变化，并评估治疗效果在前列腺癌的临床试验。方法我们已经开发出一个商业化的全自动计算机辅助检测（CAD）系统，并报告。使用该系统，扫描图像进行强度归一化，然后通过解剖区域特异性强度阈值识别和分割病变。将检测到的病变与专家标记进行比较，以评估CAD系统的准确性。根据识别的病灶计算骨扫描病灶面积、骨扫描病灶强度和骨扫描病灶计数指标，并通过分析转移性去势抵抗性前列腺癌患者（10例治疗和10例未治疗）的扫描前后，评价其在评估治疗效果方面的效用。在这项研究中，患者接受卡博替尼治疗，MET/血管内皮生长因子抑制剂导致高分辨率的骨扫描abnormality.Results我们的自动CAD系统确定骨病变像素的灵敏度为94%，特异性为89%，准确性为89%。在我们的系统得出的所有评估测量值中，发现治疗组和未治疗组之间较基线的变化存在显著差异。最重要的测量，骨扫描病变面积，显示中位数（四分位距）第6周较基线的变化为7.13%治疗组为27.61，对照组为-73.76%（45.38）卡博替尼治疗组结论本系统能准确、客观地识别和定量骨扫描中的转移瘤，允许患者间和患者内的比较。它证明了作为治疗效果的客观测量的潜力，为验证其他临床相关的结果指标奠定了基础。Nucl Med Commun 33：384-394（C）2012 Wolters Kluwer Health垂直栏Lippincott威廉姆斯& Wilkins。
Objective The development and evaluation of a computer-aided bone scan analysis technique to quantify changes in tumor burden and assess treatment effects in prostate cancer clinical trials.Methods We have developed and report on a commercial fully automated computer-aided detection (CAD) system. Using this system, scan images were intensity normalized, and then lesions were identified and segmented by anatomic region-specific intensity thresholding. Detected lesions were compared against expert markings to assess the accuracy of the CAD system. The metrics Bone Scan Lesion Area, Bone Scan Lesion Intensity, and Bone Scan Lesion Count were calculated from identified lesions, and their utility in assessing treatment effects was evaluated by analyzing before and after scans from metastatic castration-resistant prostate cancer patients: 10 treated and 10 untreated. In this study, patients were treated with cabozantinib, a MET/vascular endothelial growth factor inhibitor resulting in high rates of resolution of bone scan abnormalities.Results Our automated CAD system identified bone lesion pixels with 94% sensitivity, 89% specificity, and 89% accuracy. Significant differences in changes from baseline were found between treated and untreated groups in all assessed measurements derived by our system. The most significant measure, Bone Scan Lesion Area, showed a median (interquartile range) change from baseline at week 6 of 7.13% (27.61) in the untreated group compared with -73.76% (45.38) in the cabozantinib-treated group (P=0.0003).Conclusion Our system accurately and objectively identified and quantified metastases in bone scans, allowing for interpatient and intrapatient comparison. It demonstrates potential as an objective measurement of treatment effects, laying the foundation for validation against other clinically relevant outcome measures. Nucl Med Commun 33:384-394 (C) 2012 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.